The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global topical pain relief market reached a value of US$ 9.3 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 13.2 Billion by 2027, exhibiting a CAGR of 5.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Topical preparations for pain relief are generally available in the form of liquids, gels, powders, creams, semisolids, emulsions, patches, foams, or aerosols. They are applied on or around the site of pain or inflammation in case of strains, sprains, tendinopathy, muscle aches, and osteoarthritis. They gradually enter the bloodstream and keep the blood levels relatively constant for a certain period. At present, pharmaceutical companies around the world are focusing on developing new routes of drug administration for providing personalized treatments to patients without decreasing the efficacy of topical analgesic or pain-relieving drugs.
The increasing prevalence of chronic pain on account of diabetic neuropathy, arthritis, multiple sclerosis, fibromyalgia, and shingles represents one of the significant factors escalating the demand for topical pain relief medications across the globe. Apart from this, the rising number of individuals participating in sports activities is also positively influencing the sales of topical pain relief medications worldwide. Moreover, the growing number of cancer patients is resulting in the increasing sales of topical pain relievers via e-commerce platforms. Furthermore, leading pharmaceutical companies are introducing topical painkillers or analgesics for managing the pain of cancer patients. They are also focusing on the development of medications that simplify treatment and reduce adverse effects. This is anticipated to expand the applications of topical pain relief medications amongst elderly and pediatric populations, as well as individuals who are intolerant to other routes of administration.
IMARC Group provides an analysis of the key trends in each sub-segment of the global topical pain relief market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on therapeutic class, formulation, type and distribution channel.
Breakup by Therapeutic Class:
Breakup by Formulation:
Breakup by Type:
Breakup by Distribution Channel:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Advacare Pharma, Exzell Pharma Inc., Glaxosmithkline Plc, Johnson & Johnson, Novartis AG, Pfizer Inc., Reckitt Benckiser Group Plc, Sanofi S.A., Sun Pharmaceutical Industries Limited and Topical Biomedics Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Therapeutic Class, Formulation, Type, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Advacare Pharma, Exzell Pharma Inc., Glaxosmithkline Plc, Johnson & Johnson, Novartis AG, Pfizer Inc., Reckitt Benckiser Group Plc, Sanofi S.A., Sun Pharmaceutical Industries Limited and Topical Biomedics Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at